Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells.

Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells.
复制标题

分泌对 PPD 反应的人 T 细胞系的迁移抑制因子:对其抗原特异性、MHC 限制以及使用 Epstein-Barr 病毒转化的 B 细胞系作为抗原呈递细胞的要求的研究。

DOI:
--
复制
发表时间:
1984
期刊:
影响因子:
6.4
通讯作者:
P. Lachmann
P. Lachmann
中科院分区:
医学2区
文献类型:
--
作者:
A. Vyakarnam;P. Lachmann

文献摘要

被引文献

相似文献

两个PPD反应性T细胞系和两个克隆来自他们的特点。将这些细胞系在含I1-2的培养基中保持10- 1 - 2周。通过有限稀释法从未克隆的株系衍生克隆,并在培养物中保持12周。克隆效率为1%。克隆和未克隆的细胞系在增殖试验中对结核菌素具有高度反应性,并在抗原刺激后产生迁移抑制因子。这两种功能都依赖于抗原呈递细胞的加入,并由MHC的II类分子进行遗传调节。每个未克隆系和源自它们的克隆仅受自体宿主的DR等位基因之一的限制。参与抗原呈递的细胞类型的分析表明,巨噬细胞和EB病毒转化的B细胞系诱导与PPD培养的T细胞系和克隆的增殖和MIF分泌。表型研究表明,细胞为绵羊E+、OKT 4+、OKT 8-和HLA-DR+。
Two PPD-reactive T-cell lines and two clones derived from them have been characterized. The lines were maintained for a period of 10-12 weeks in I1-2 containing medium. The clones were derived from the uncloned lines by the limiting dilution method and maintained in culture for 12 weeks. The cloning efficiency was 1%. Both the cloned and the uncloned lines were highly reactive to tuberculin in a proliferation assay and produced migration inhibition factors following antigenic stimulation. Both these functions were dependent on the addition of antigen-presenting cells and genetically regulated by Class II molecules of the MHC. Each uncloned line and the clones derived from them were restricted by just one of the DR alleles of the autologous host. An analysis of cell types involved in antigen presentation showed that macrophages and Epstein-Barr virus-transformed B-cell lines induced both proliferation and MIF secretion in the T-cell lines and clones cultured with PPD. Phenotypic studies indicate that the cells are Sheep E+, OKT4+, OKT8- and HLA-DR+.